news

29-Apr-2019 Last updated on 25-Apr-2019 at 15:18 GMT  With OptiPEA (Palmitoylethanolamide), Innexus Nutraceuticals offers companies the opportunity to benefit from the current world wide interest for the endocannabinoid system, the rising demand for a safe solution for chronic pain and the consumer trend toward branded, transparent and sustainable ingredients.​ Pain relief in crisis​ Chronic pain management presents […]

GMP grade Palmitoylethanolamide – OptiPEA® 26-Jun-2019  Nijmegen, The Netherlands – Innexus Nutraceuticals announced the worldwide launch of OptiPEA® (www.optipea.com), EU GMP grade palmitoylethanolamide. Safety, quality and reliability are rising standards for nutraceutical ingredients and customers should not expect less. That is why dietary supplement companies are relying more and more on branded ingredients for their products. OptiPEA® Quality “We

26-Jun-2019 Transparency, certification, sustainability, branding. With OptiPEA (palmitoylethanolamide), Innexus Nutraceuticals offers companies the opportunity to effectively respond to the ever-increasing demand for chronic pain relief. The use of opioids takes epidemic forms and CBD (cannabinoids) encounters limits with regard to regulations and quality criteria. OptiPEA offers a proven and branded alternative that is immediately available

Uncertainty around CBD products’ status in the supplements sector has led to a reluctance to include CBD in supplements, says Innexus Nutraceuticals as it look to push forward with its PEA-based CBD alternative. Netherlands-based Innexus Nutraceuticals says uncertainty around CBD produc]. ts’ status in the supplements sector has led to a reluctance to include CBD